Stocks · News reference
Liminatus Pharma shares are trading higher after the company announced its stock transfer to the Nasdaq Capital Market and an extension to meet minimum bid price compliance.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Veeva Systems (NYSE:VEEV) shares increased by 8.7% to $266.15 during Wednesday's after-market session. The market value of their outstanding shares is at $40.0 billion. The company's, Q2 earnings came
Liminatus Pharma shares are trading lower. The company announced it has engaged Synex Consulting to support the clinical development of IBC101, CD19xCD22 bivalent CAR-T cell therapy candidate.
Liminatus Pharma Engages Synex Consulting To Support Clinical Development Of IBC101, CD19xCD22 Bivalent CAR-T Cell Therapy Candidate